Spots Global Cancer Trial Database for recurrent brain neoplasm
Every month we try and update this database with for recurrent brain neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme | NCT02575027 | Glioblastoma Recurrent Brain... | Palliative Radi... Questionnaire A... Radiation Thera... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | NCT02323880 | Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli... | Pharmacological... Selinexor | 12 Months - 21 Years | Children's Oncology Group | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | NCT02521090 | Adult Brain Gli... Adult Gliosarco... Recurrent Brain... | EGFRBi-Armed Au... Laboratory Biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | NCT02661282 | Cytomegalovirus... Glioblastoma Gliosarcoma Malignant Gliom... Recurrent Brain... Recurrent Gliob... | Autologous Cyto... Laboratory Biom... Temozolomide Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors | NCT02754544 | Brain Neoplasm Metastatic Mali... Recurrent Brain... | Direct Electroc... Electrocorticog... | 18 Years - | M.D. Anderson Cancer Center | |
| Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors | NCT02754544 | Brain Neoplasm Metastatic Mali... Recurrent Brain... | Direct Electroc... Electrocorticog... | 18 Years - | M.D. Anderson Cancer Center | |
| 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors | NCT02167204 | Metastatic Mali... Primary Brain N... Recurrent Brain... | Computed Tomogr... Fluorothymidine... Positron Emissi... | 18 Years - | University of Washington | |
| Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery | NCT03071913 | Central Nervous... Localized Brain... Metastatic Mali... Recurrent Brain... | Biospecimen Col... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors | NCT02167204 | Metastatic Mali... Primary Brain N... Recurrent Brain... | Computed Tomogr... Fluorothymidine... Positron Emissi... | 18 Years - | University of Washington | |
| 18F-DOPA-PET in Planning Surgery in Patients With Gliomas | NCT02020720 | Malignant Gliom... Recurrent Brain... | Biopsy Computed Tomogr... Diffusion Weigh... Fluorine F 18 F... Laboratory Biom... Perfusion Magne... Positron Emissi... Therapeutic Con... | 7 Years - | Mayo Clinic | |
| EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | NCT02521090 | Adult Brain Gli... Adult Gliosarco... Recurrent Brain... | EGFRBi-Armed Au... Laboratory Biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | NCT02323880 | Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli... | Pharmacological... Selinexor | 12 Months - 21 Years | Children's Oncology Group | |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | NCT02323880 | Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli... | Pharmacological... Selinexor | 12 Months - 21 Years | Children's Oncology Group | |
| Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors | NCT02389309 | Advanced Malign... Recurrent Brain... Recurrent Malig... Refractory Brai... | Cyclophosphamid... Dasatinib Laboratory Biom... Temsirolimus | 12 Months - 20 Years | M.D. Anderson Cancer Center | |
| Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | NCT04588246 | Anatomic Stage ... Metastatic Brea... Metastatic Dige... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Prognostic Stag... Recurrent Brain... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... | Memantine Quality-of-Life... Questionnaire A... Stereotactic Ra... Whole-Brain Rad... | 18 Years - | NRG Oncology | |
| Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | NCT02658981 | Glioblastoma Gliosarcoma Recurrent Brain... | Anti-LAG-3 Mono... Anti-PD-1 Pharmacological... Laboratory Biom... Anti-CD137 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | NCT02359565 | Constitutional ... Lynch Syndrome Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Diffu... Recurrent Medul... Refractory Brai... Refractory Diff... Refractory Epen... Refractory Medu... | Biospecimen Col... Conventional Ma... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Dynamic Suscept... Magnetic Resona... Pembrolizumab | 1 Year - 30 Years | National Cancer Institute (NCI) | |
| 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors | NCT02167204 | Metastatic Mali... Primary Brain N... Recurrent Brain... | Computed Tomogr... Fluorothymidine... Positron Emissi... | 18 Years - | University of Washington | |
| 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors | NCT02167204 | Metastatic Mali... Primary Brain N... Recurrent Brain... | Computed Tomogr... Fluorothymidine... Positron Emissi... | 18 Years - | University of Washington |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
